Vilazodone (Viibryd) and Ketamine Therapy | Tovani Health
Viibryd (Vilazodone) — SSRI / 5-HT1A partial agonist
Verdict at Tovani Health
Compatible; standard antidepressant-class monitoring, not the older SS framing.
Vilazodone and ketamine are compatible. As an SSRI plus 5-HT1A partial agonist, vilazodone is covered by the same Veraart 2021 systematic review that found no documented serotonin syndrome with ketamine plus serotonergic antidepressants. We track BP and general antidepressant-class considerations rather than a specific SS protocol.
If you take Viibryd regularly and are considering at-home ketamine therapy, the combination is safe with monitoring or dose adjustment. This page covers the brief pharmacologic context and what we do at intake.
How Viibryd interacts with ketamine
Vilazodone inhibits serotonin reuptake and partially activates 5-HT1A receptors. Take with food for absorption. Ketamine is not meaningfully serotonergic, so historical SS framing has been retired.
What we do at intake
Disclose dose and confirm you are taking it with food. Tell us about CYP3A4 inhibitors or inducers in your regimen. Standard serotonin-syndrome briefing applies.
Bottom line
Vilazodone and ketamine are compatible. As an SSRI plus 5-HT1A partial agonist, vilazodone is covered by the same Veraart 2021 systematic review that found no documented serotonin syndrome with ketamine plus serotonergic antidepressants. We track BP and general antidepressant-class considerations rather than a specific SS protocol.
Frequently Asked Questions
Does Viibryd's 5-HT1A activity change anything for KAP?
Functionally, no. The serotonin reuptake component is what drives the interaction profile we plan around.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Viibryd (Vilazodone) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Sources
The verdict and clinical guidance on this page are based on the following peer-reviewed literature and FDA prescribing information.
- Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al.. International Journal of Neuropsychopharmacology. 2021. PMID: 34170315
Systematic review of pharmacodynamic interactions between ketamine and psychiatric medications used in depression treatment.
- Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. Alnefeesi Y, Chen-Li D, Krane E, et al.. Journal of Psychiatric Research. 2022. PMID: 35688035
Meta-analysis of 2,665 patients across 79 studies — 45% response and 30% remission with ketamine in treatment-resistant depression.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 15, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.